NCT04934761

Brief Summary

By observing the changes of P-V loop in capacity shock intervention Under Goal-directed Hemodynamic Management in patients undergoing total knee replacement, we investigate the effect of capacity shock on cardiac contractility and work in order to seek a more effective target plan of capacity shock for intraoperative patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

May 25, 2021

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 10, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 22, 2021

Completed
Last Updated

June 22, 2021

Status Verified

June 1, 2021

Enrollment Period

11 months

First QC Date

May 25, 2021

Last Update Submit

June 19, 2021

Conditions

Outcome Measures

Primary Outcomes (15)

  • Ees

    Ees(End-systole Elasticity,mmHg/ml)

    Baseline,After induction

  • Ees

    Ees(End-systole Elasticity,mmHg/ml)

    Immediately after the intervention,complete of the first round of the fluid challenge

  • Ees

    Arterial elasticity is an invasively determined parameter of arterial load that is inversely related to arterial compliance

    Immediately after the intervention,complete of the second round of the fluid challenge

  • Ees

    Ees(End-systole Elasticity,mmHg/ml)

    1h after the first fluid challenge

  • Ees

    Ees(End-systole Elasticity,mmHg/ml)

    At the end of surgery

  • SW

    SW(Stroke Volume,mmHg·ml)

    Baseline,after induction

  • SW

    SW(Stroke Volume,mmHg·ml)

    Immediately after the intervention,complete of the first round of the fluid challenge

  • SW

    SW(Stroke Volume,mmHg·ml)

    Immediately after the intervention,complete of the second round of the fluid challenge

  • SW

    SW(Stroke Volume,mmHg·ml)

    1h after the first fluid challenge

  • SW

    SW(Stroke Volume,mmHg·ml)

    At the end of surgery

  • Ea

    Ea(Arterial elasticity, mmHg·ml)

    Baseline,after induction

  • Ea

    Ea(Arterial elasticity, mmHg·ml)

    Immediately after the intervention,complete of the first round of the fluid challenge

  • Ea

    Ea(Arterial elasticity, mmHg·ml)

    Immediately after the intervention,complete of the second round of the fluid challenge

  • Ea

    Ea(Arterial elasticity, mmHg·ml)

    1h after the first fluid challenge

  • Ea

    Ea(Arterial elasticity, mmHg·ml)

    At the end of surgery

Study Arms (2)

capacity shock

EXPERIMENTAL

2ml/kg succinylateol gelatin

Procedure: Fluid challenge strategy

routine management

OTHER

conventional strategy

Procedure: conventional strategy

Interventions

Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV\< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV \<10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV\<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.

capacity shock

4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.

routine management

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASAI-II age 40- 70 weight 48 - 72 kg.

You may not qualify if:

  • Body mass index \>30 or \<15 kg/m2 Valve heart disease Left ventricular ejection fraction (LVEF) is less than 50% History of lung disease Preoperative arrhythmic disorder Permanent pacemaker Need for mechanical heart Support, Severe extrinsic vascular disease Valve dysfunction OED monitoring probe insertion contraindications Patients with preoperative assessments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangzhou Red cross hospital

Guangzhou, Guangdong, 510220, China

Location

Study Officials

  • Cao Yang

    Guangzhou Red Cross Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director of Anesthesiology Physicians

Study Record Dates

First Submitted

May 25, 2021

First Posted

June 22, 2021

Study Start

June 1, 2020

Primary Completion

May 1, 2021

Study Completion

June 10, 2021

Last Updated

June 22, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations